Adamis Pharmaceuticals Corporation (ADMP) EPS Estimated At $-0.15

March 14, 2018 - By Vivian Park

 Adamis Pharmaceuticals Corporation (ADMP) EPS Estimated At $ 0.15

Analysts expect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) to report $-0.15 EPS on March, 29. The stock decreased 2.63% or $0.1 during the last trading session, reaching $3.7. About 745,153 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since March 15, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. Maxim Group initiated it with “Buy” rating and $16 target in Tuesday, December 1 report. The rating was maintained by Maxim Group with “Buy” on Monday, August 21. The firm has “Buy” rating given on Tuesday, September 12 by Raymond James. The rating was maintained by Raymond James on Monday, December 4 with “Buy”. The firm has “Buy” rating given on Monday, June 12 by Maxim Group. The company was maintained on Thursday, July 21 by Maxim Group.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $123.53 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

More notable recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: which released: “Adamis Pharmaceuticals: Elucidating The Potential Commercial Partnership For …” on February 25, 2018, also with their article: “Adamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst” published on June 01, 2017, published: “Adamis Pharmaceuticals: A Rocket Still On The Launchpad” on November 30, 2017. More interesting news about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) were released by: and their article: “Adamis Pharmaceuticals: A Rocket Counting Down To Lift-Off” published on October 25, 2017 as well as‘s news article titled: “Can Adamis Bleed Mylan Dry?” with publication date: December 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: